Buyout includes $51.9 million payout to Synthes' top executive

12/5/2011 | MassDevice.com (Boston)

Michel Orsinger, CEO of Synthes, will receive a $51.9 million payout as part of a $21.3 billion acquisition by Johnson & Johnson. The buyout, which is expected to be completed early next year, will allow Johnson & Johnson to add Synthes to its DePuy unit, with Orsinger taking over as head of the company's new global orthopedics team.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT